Global Respiratory Disorders Novel Drugs and Smart Devices Research Report 2018 Featuring 160 Leading Companies & Organisations

News provided by

Mar 13, 2018, 08:15 ET

DUBLIN, March 13, 2018 /PRNewswire/ --

The "Novel Drugs and Smart Devices for Respiratory Disorders, 2018-2030" report has been added to ResearchAndMarkets.com's offering.

The Novel Drugs and Smart Devices for Respiratory Disorders, 2018-2030' report provides a comprehensive study on the current landscape of novel therapies and smart devices being evaluated for the treatment of asthma, COPD and cystic fibrosis.

The field has captured the interest of several drug developers, both small and large companies. With several novel drug candidates in development, we anticipate the market to witness continued growth over the next 5-10 years.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030.

The research, analysis and insights presented in this report include potential sales of novel therapies, as well as smart inhalers that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Respiratory Disorders and the Healthcare Burden
3.2. Type of Respiratory Disorders
3.3. Prevalence of Respiratory Disorders
3.4. Respiratory Disorders with High Unmet Need

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Respiratory Disorders Pipeline: Distribution by Indication

5. UNMET NEED ANALYSIS
5.1. Chapter Overview
5.2. Unmet Need Analysis in Asthma
5.3. Unmet Need Analysis in COPD
5.4. Unmet Need Analysis in Cystic Fibrosis

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. AbbVie
6.3. AstraZeneca
6.4. Boehringer Ingelheim
6.5. Chiesi Pharmaceuticals
6.6. GlaxoSmithKline
6.7. Novartis
6.8. Teva Pharmaceutical
6.9. Vertex Pharmaceuticals
6.10. CURx Pharmaceuticals
6.11. Laurent Pharmaceuticals
6.12. Sanofi
6.13. Gilead Sciences
6.14. AB Science

7. DRUG PROFILES
7.1. Chapter Overview
7.2. Marketed/Approved Drugs
7.3. Late Stage Drug Candidates

8. KEY INSIGHTS
8.1. Chapter Overview
8.2. Asthma, COPD and Cystic Fibrosis: Pipeline Analysis by Size of Players
8.3. Asthma: Pipeline Analysis by Phase of Development, Drug Class, Type of Molecule and Mode of Administration
8.4. COPD: Pipeline Analysis by Phase of Development, Drug Class, Type of Molecule and Mode of Administration
8.5. Cystic Fibrosis: Pipeline Analysis by Phase of Development, Drug Class, Type of Molecule and Mode of Administration

9. SMART INHALERS: INTRODUCTION AND DEVELOPER LANDSCAPE
9.1. Chapter Overview
9.2. Internet of Things (IoT)
9.3. Evolution of Inhalers
9.4. Inhalers and The Cost of Non-Adherence
9.5. Smart Inhalers

10. REGULATORY LANDSCAPE FOR SMART INHALERS
10.1. Chapter Overview
10.2. Rise of Connected Devices
10.3. Regulatory Approval of Combination Products in the US
10.4. Regulatory Approval of Combination Products in Europe
10.5. Regulatory Approval of Combination Products in Canada
10.6. Regulatory Approval of Combination Products in Brazil
10.7. Regulatory Approval of Combination Products in Mexico
10.8. Regulations of Combination Products in Argentina
10.9. Regulatory Approval of Combination Products in Australia
10.10. Regulatory Approval of Combination Products in Japan
10.11. Regulatory Approval of Combination Products in China
10.12. Regulations of Combination Products in India
10.13. Regulation of Combination Products in South Korea
10.14. Regulation of Combination Products in Saudi Arabia
10.15. Regulation of Combination Products in United Arab Emirates (UAE)
10.16. Smart Inhalers: Demonstrating Safety, Effectiveness and Performance

11. SMART INHALERS: MARKET SIZE AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall Smart Inhalers Market, 2018-2030
11.4. Overall Smart Inhalers Market: Distribution by Geography

12. RESPIRATORY DISORDERS: NOVEL THERAPEUTICS, MARKET SIZE AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Respiratory Disorders: Overall Novel Therapeutics Market, 2018-2030
12.4. Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Indication
12.5. Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Drug Class
12.6. Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Key Players
12.7. Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Type of Molecule
12.8. Respiratory Disorders: Overall Novel Therapeutics Market: Distribution by Route of Administration
12.9. Respiratory Disorders: Overall Novel Therapeutics Market: Distribution by Geography

13. CONCLUSION
13.1. With High Prevalence and Lack of Efficient Treatment Options, Asthma, COPD and Cystic Fibrosis Continue to Pose Enormous Burden on the Healthcare System
13.2. To Improve Disease Management, Several Stakeholders, including Well Established Pharma Players, are Exploring Novel Opportunities
13.3. LABA/LAMA and ICS/LAMA/LABA Fixed Dose Combinations are Redefining Treatment Options for COPD; Biologics are Expected to Become Popular for Asthma
13.4. High Success of CFTR Modulators Has Offered Hope in the Cystic Fibrosis Segment; Combination Therapies are Likely to Emerge in the Near Future
13.5. Despite These Advancements, High Rate of Non-adherence, Delayed/Mis-Diagnosis and Lack of Personalized Therapies are amongst the pressing Unmet Needs
13.6. With Various Companies Adopting Digital Solutions to Overcome Specific Patient Needs, Smart Inhalers are Likely to Offer Significant Opportunities
13.7. As the Recently Approved Therapies Provide More Evidence of their Benefits, the Overall Market is Anticipated to Grow at a Steady Pace

14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Alex Stenzler, Founder and President, Novoteris
14.3 Dinu Sen, CEO, CURx Pharmaceuticals
14.4 Antonio Anzueto, Pulmonologist, University of Texas Health Science Center
14.5 Richard Moss, Pediatric Pulmonologist, Lucile Packard Children's Hospital, Stanford University
14.6 Dinesh Srinivasan, Director, Anthera Pharmaceuticals

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

3M
AB Science
AbbVie
Abeome
Ablynx
Adherium
Aerobit
Afimmune
Airnest
AlgiPharma
Almirall
Alphabet
American College of Chest Physicians
American Thoracic Society
Amgen
Amiko
AnaptysBio
Anthem
Anthera
Aptar Pharma
Aridis Pharmaceuticals
Ario Pharma
Array BioPharma
Artax Biopharma
ASLAN Pharmaceuticals
Asthma UK
AstraZeneca
Atopix Therapeutics
Australian Advisory Committee on Prescription Medicines
Axikin Pharmaceuticals
Bayer
BIOCORP
Biomarck Pharmaceuticals
BioMed X
Boehringer Ingelheim
British Lung Foundation
Celtaxsys
Chiesi Pharmaceuticals
Cipla
Circassia Pharmaceuticals
Cohero Health
Concert Pharmaceuticals
Corbus Pharmaceuticals
CRISPR Therapeutics
Crux Product Design
CURx Pharmaceuticals
Cystic Fibrosis Foundation
Dermira
DS Biopharma
Duke-NUS Academic Medical Centre
Dynavax
Editas Medicine
Eleventa
Ethris
Eularis
European Respiratory Society
EURRUS Biotech
Express Scripts
FindAir
Five Prime Therapeutics
Flatley Discovery Lab
Folium Optics
Foresee Pharmaceuticals
Forum of International Respiratory Societies
Galapagos
Gecko Health Innovations
Geisinger
Genzyme
Gilead Sciences
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Global Initiative for Asthma (GINA)
Global Initiative for Chronic Obstructive Lung Disease
Grifols
Guangzhou Medical University
H&T Presspart
Hanmi Pharmaceutical
Health Care Originals
Health Factors
HealthCore
Hewlett Packard Labs
Hikma Pharmaceuticals
Hydra Biosciences
IBM
ID Pharma
Imperial College London
Innoviva
Insmed
Inspiro Medical
International Federation of Pharmaceutical Manufacturers and Associations
Inventiva
Ivax
Janssen Biotech
Japanese Ministry of Health, Labour and Welfare
Jvion
KBP Biosciences
Koronis BioMedical Technologies
Laurent Pharmaceuticals
Ligand Pharmaceuticals
Mariposa Health
MedImmune
Merck
MicroDose Therapeutx
Moderna Therapeutics
MorphoSys
Mylan
National Health Service (NHS)
NIHR Manchester Biomedical Research Centre
Novartis
Novimmune
Novoclem Therapeutics
Novoteris
Ono Pharmaceuticals
OPKO Health
Orexo
Palobiofarma
Panmira Pharmaceuticals
Paranta Biosciences
Parion Sciences
Pearl Therapeutics
Pfizer
Pharmaxis
Pieris Pharmaceuticals
Polyphor
Propeller Health
ProQR Therapeutics
Proteostasis Therapeutics
Pulmagen Therapeutics
Pulmatrix
Qualcomm
Reata Pharmaceuticals
Regeneron Pharmaceuticals
Resolve Digital Health
RespiVert
REX Medical
Rigel Pharmaceuticals
Roche
Sanofi
Savara Pharmaceuticals
Singapore Health Services (SingHealth)
Southern Research
Spyryx Biosciences
Sterna Biologicals
Sunovion
Sunrise Labs
Synairgen
Syqe Medical
Teijin Pharma
Teva Pharmaceutical
Therapeutics Good Administration (TGA)
University of California Berkeley (UCB)
University of Iowa
US Food and Drug Administration
Vectura
Verona Pharma
Vertex Pharmaceuticals
Weill Cornell Medicine
World Health Organization
Xencor
YUNGJIN Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/research/7rndpp/global?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets